MLXIPL and neoplasm: Supporting the hypothesis that pharmacological inhibition of ChREBP activity is of interest for cancer treatment, SBI-993 also significantly reduced SNU475, Huh7 and BNL CL.2 cell proliferation and xenograft tumor development when nude mice were treated daily with 50 mg/kg of SBI-993 for 3 consecutive weeks (Fig. 9g–i and Supplementary Fig. 14f, g).